PR OUT BioElectronics (OTC: BIEL) New Clinic

PR OUT

BioElectronics (OTC: BIEL) New Clinical Trial

Thrilled to announce the start of an investigator initiated study evaluating our FDA cleared device for its ability to also reduce pain in patients with thumb carpometacarpal (CMC) joint osteoarthritis (OA). Stanford University initiated a study entitled "Pulsed Electromagnetic Field (PEMF) Therapy in Thumb CMC Arthritis" (ClinicalTrials.gov Identifier: NCT05315297) Osteoarthritis is the second-most common musculoskeletal disorder, leading to pain and functional limitations with a high social and economic burden. OA can affect every joint in the body, but it is most common in the knee, hip, spine, and hand. Within the hand, the thumb base is the most affected single joint. (https://lnkd.in/e-jPdpqF) #clinicaltrial #osteoarthritis #painrelief #painmanagement #drugfreetreatment #stanforduniversity #research $BIEL
pknopick@eandecommunications.com